CXCR2 and non-small cell lung carcinoma: We show here that tumors of younger patients with NSCLC are enriched for oncogenic driver alterations, are less immunogenic overall, and are less likely to be high expressors of immunotherapy targets, although this was not the case for all tested markers (e.g., CXCR2).